Schedule 1—Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Note: See sections 5 and 6.

Permissible in	gredients and requirements		
Column 1	Column 2	Column 3	Column 4
2180	FABIANA IMBRICATA	A, H	
2181	FAGOPYRUM ESCULENTUM	A, H	
2182	FAGUS GRANDIFOLIA	A, H	
2183	FAGUS SYLVATICA	A, H	
2184	FARNESOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2185	FARNESYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as part of a flavour or fragrance proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%. When used in a fragrance, the total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
2186	FAST GREEN FCF	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			administration.
2187	FENCHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2188	FENCHYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2189	FENCHYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2190	FENNEL BITTER SEED DRY	A, E, H	When used in oral medicines, the following warning statements are required on the label: - (CHILD3) 'Use in children under 12 years is not recommended' - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)'

			- (BREASF) 'Do not use while breastfeeding.'
2191	FENNEL LEAF	Е	
2192	FENNEL OIL	A, E, H	Methyl chavicol is a mandatory component of fennel oil. When the concentration of methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL, a restricted flow insert must be fitted on the container, and the following warning statement is required on the label: - (CHILD) 'Keep out of reach of children (or words to that effect).' The maximum daily dose must provide no more than 150 mg of fennel oil. When used in oral medicines, the following warning statements are required on the label: - (CHILD3) 'Use in children under 12 years is not recommended.' - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect).' - (BREASF) 'Do not use while breastfeeding.'
2193	FENNEL SWEET SEED DRY	А, Е, Н	When used in oral medicines, the following warning statements are required on the label: - (CHILD3) 'Use in children under 12 years is not recommended' - (PREGNT2) 'Do not use if pregnant or likely to become

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.'
2194	FENUGREEK	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2195	FENUGREEK OIL	E	Fenugreek oil is permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2196	FERRIC AMMONIUM CITRATE	A, E, H	When for internal use, iron is a mandatory component of ferric ammonium citrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of

elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

2197 FERRIC CHLORIDE A, E, H

When for internal use, iron is a mandatory component of ferric chloride.

When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.

If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use, iron is a

2198 FERRIC CHLORIDE HEXAHYDRATE

A, E, H

dose of no more than 24 mg of iron.

If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron.

In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%).

mandatory component of ferric

chloride hexahydrate.
When for internal use, the medicine must contain a daily

Divided preparations with a

dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). When for internal use, iron is a mandatory component of ferric glycerophosphate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the

2199 FERRIC GLYCEROPHOSPHATE A, E, H

primary pack must contain no

more than 750 mg of iron (excluding iron oxides when

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2200	FERRIC OXIDE	Е	
2201	FERRIC PHOSPHATE	Н	Only for use as an active homoeopathic ingredient.
2202	FERRIC PYROPHOSPHATE	A, H	When for internal use, iron is a mandatory component of ferric pyrophosphate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the

primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

2203 FERROSOFERRIC OXIDE E

When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content.

When used in divided preparations for internal use, the concentration in the medicine must be no more than

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			10 mg per dosage unit.
2204	FERROSOFERRIC PHOSPHATE	Н	Only for use as an active homoeopathic ingredient.
2205	FERROUS FUMARATE	A, H	When for internal use, iron is a mandatory component of ferrous fumarate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires

			volume 3
			the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2206	FERROUS GLUCONATE	A, E, H	When for internal use, iron is a mandatory component of ferrous gluconate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Vol	lume	3
V O	unin	J

specific iron-deficiency related claims, the medicine requires the following statement on the medicine label:
- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

2207 FERROUS GLUCONATE DIHYDRATE

A, E, H

When for internal use, iron is a mandatory component of ferrous gluconate dihydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.

If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			indicated for a constant of
			indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2208	FERROUS IODIDE	Н	Only for use as an active homoeopathic ingredient.
2209	FERROUS LACTATE TRIHYDRATE	A, E, H	When for internal use, iron is a mandatory component of ferrous lactate trihydrate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 3

container are required to have a child resistant closure.

When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label:

- (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

2210 FERROUS PHOSPHATE OCTAHYDRATE

A, E, H

When for internal use, iron is a mandatory component of ferrous phosphate octahydrate. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250

			milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2211	FERROUS PICRATE	Н	Only for use as an active homoeopathic ingredient.
2212	FERROUS SULFATE	A, E, H	When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 3

Undivided preparations containing more than 250 milligrams of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

2213 FERROUS SULFATE HEPTAHYDRATE

A, E, H

When for internal use, iron is a mandatory component of ferrous sulfate heptahydrate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.

If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are

			required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the medicine requires the following statement on the medicine label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2214	FERULA ASSA-FOETIDA	A, E, H	
2215	FERULA FOETIDA	A, E, H	
2216	FERULA GALBANIFLUA	A, E, H	
2217	FERULA RUBRICAULIS	A, E, H	
2218	FERULA SUMBUL	A, H	
2219	FERULIC ACID	E	Only for use in topical medicines for dermal application.
2220	FESTUCA ELATIOR	A, H	
2221	FEVERFEW HERB DRY	A, H	
2222	FEVERFEW HERB POWDER	A, H	
2223	FICUS CARICA	A, E, H	
2224	FICUS PUMILA	A, H	
2225	FIG	Е	
2226	FIG DRY	A, H	
2227	FILIPENDULA ULMARIA	А, Н	Methyl salicylate is a mandatory component of Filipendula ulmaria. Not to be included in medicines for use in the eye or

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 3

on damaged skin. When used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device is ergonomically difficult for young children to accomplish. The following warning statement is required on the medicine label: - (METSAL) 'Contains methyl salicylate' (or words to that effect). When for use in topical medicines for dermal application: i) the concentration of methyl salicylate in the medicine must not be more than 25%; ii) the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become

			pregnant' (or words to that effect);
			- (CHILD4) 'Do not use [this
			product/insert name of product]
			in children 6 years of age or
			less';
			- (SENS) 'Application to skin
			may increase sensitivity to
			sunlight.' (or words to that
			effect);
			- (AVOID) 'Avoid prolonged
			exposure in the sun' (or words to that effect);
			iii) if the concentration of
			methyl salicylate in the
			medicine is greater than 1%,
			the following warning
			statement is required on the
			medicine label:
			- (IRRIT) 'If irritation
			develops, discontinue use'.
2228	FIR BALSAM ABSOLUTE	E	Permitted for use only in
			combination with other
			permitted ingredients as a
			fragrance.
			If used in a fragrance the total fragrance concentration in a
			medicine must be no more than
			1%.
2229	FIR NEEDLE OIL CANADIAN	A , E	_
2230	FIR NEEDLE OIL SIBERIAN	A, E	
2231	FIRMIANA SIMPLEX	A, E, H	
2232	FISH OIL - RICH IN OMEGA-3 ACIDS	A	Only for use in oral medicines.
2233	FLEMINGIA MACROPHYLLA	A, H	
2234	FLOUVE OIL	E	Permitted for use only in
			combination with other permitted ingredients as a
			flavour or a fragrance.
			If used in a flavour the total
			flavour concentration in a
			medicine must be no more than
			5%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2235	FLUORESCEIN SODIUM	Е	
2236	FOENICULUM VULGARE	A, E, H	When used in oral medicines, the following warning statements are required on the label: - (CHILD3) 'Use in children under 12 years is not recommended' - (PREGNT2) 'Do not use if pregnant or likely to become pregnant (or words to that effect)' - (BREASF) 'Do not use while breastfeeding.' When the plant preparation is oil or distillate, methyl chavicol is a mandatory component and the maximum daily dose must provide no more than 150 mg of the plant preparation. When the plant preparation is oil or distillate and the concentration of methyl chavicol in the medicine is more than 5%, the nominal capacity of the container must be no more than 25mL, a restricted flow insert must be fitted on the container, and the following warning statement is required on the label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
2237	FOLIC ACID	A	When for internal use, the maximum recommended daily dose must not provide more than 500 micrograms of folic acid. When the medicine contains a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			combination of folic acid, folinic acid or levomefolic acid, the medicine must not provide more than a combined total of 500 micrograms of folic acid, folinic acid and levomefolic acid per maximum recommended daily dose.
2238	FOOD ORANGE 6	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
2239	FOOD ORANGE 7	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
2240	FOOD RED 13	Е	Permitted for use only as a colour for topical use.
2241	FORMALDEHYDE/MELAMINE/T OSYLAMIDE COPOLYMER	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 10%.
2242	FORMIC ACID	E, H	Formic acid must only be included in medicines: (a) as an active homoeopathic ingredient; or (b) when in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total concentration of flavour proprietary excipient formulations containing formic acid must not be more than 5% of the total medicine. The maximum recommended daily dose of the medicine must not provide more than

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			150 mg of formic acid. The total concentration of formic acid in the medicine must not be more than 0.5%.
2243	FORSYTHIA SUSPENSA	A, H	
2244	FORTIFIED WINE	Е	Ethanol is a mandatory component of fortified wine.
2245	FRACTIONATED COCONUT OIL	Е	
2246	FRACTIONATED PALM KERNEL OIL	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2247	FRAGARIA CHILOENSIS	A, E, H	
2248	FRAGARIA VESCA	A, E, H	
2249	FRAGARIA VIRGINIANA	A, E, H	
2250	FRAGARIA X ANANASSA	A, E, H	
2251	FRANGULA BARK DRY	A, H	Glucofrangulins calculated as glucofrangulin A is a mandatory component of Frangula bark dry. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when

abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect]. When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label: - (LAX1) 'Drink plenty of water' [or words to that effect]. When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and - (LAX4) 'This product may have laxative effect'. When used in oral medicines, if the maximum recommended daily dose contains less than 10 mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children

- (CHILD3) 'Use in children under 12 years is not recommended';

- (LAX1) 'Drink plenty of water' [or words to that effect]; and
- (LAX2) 'Prolonged use may cause serious bowel problems'.

2252 FRANGULA BARK POWDER A, H Glucofrangulins calculated as glucofrangulin A is a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 3

mandatory component of
Frangula bark powder.
When used in oral medicines,
if the maximum recommended
daily dose contains more than
10 mg of hydroxyanthracene
derivatives the medicine
requires the following warning
statements on the medicine
label:

- (CHILD3) 'Use in children under 12 years is not recommended';
- (LAX2) 'Prolonged use may cause serious bowel problems'; and
- (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product [or words to that effect]'.

When promoted or marketed as a laxative, the medicine requires the following warning statement on the medicine label:

- (LAX1) 'Drink plenty of water [or words to that effect]'. When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
 - (LAX4) 'This product may
- have laxative effect'.

 When used in oral medicines, if the maximum recommended daily dose contains less than 10

mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX1) 'Drink plenty of water [or words to that effect]'; and - (LAX2) 'Prolonged use may cause serious bowel problems'. When for oral use, 2253 FRANGULA PURSHIANA A, H hydroxyanthracene derivatives calculated as cascaroside A is a mandatory component of Frangula purshiana. When used in oral medicines, if the maximum recommended daily dose contains more than 10 mg of hydroxyanthracene derivatives the medicine requires the following warning statements on the medicine label: - (CHILD3) 'Use in children under 12 years is not recommended'; - (LAX2) 'Prolonged use may cause serious bowel problems'; and - (LAX3) 'Do not use when abdominal pain, nausea or vomiting are present, or if you develop diarrhoea. If you are pregnant or breast feeding, seek the advice of a healthcare professional before taking this product' [or words to that effect]. When promoted or marketed as a laxative, the medicine requires the following warning

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 3

statement on the medicine label:

- (LAX1) 'Drink plenty of water' [or words to that effect]. When not promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
- (LAX5) 'This product contains [name of the herb(s) or the chemical component(s)]'; and
- (LAX4) 'This product may have laxative effect'.

 When used in oral medicines, if the maximum recommended daily dose contains less than 10
- mg of hydroxyanthracene derivatives and is promoted or marketed as laxative, the medicine requires the following warning statements on the medicine label:
- (CHILD3) 'Use in children under 12 years is not recommended';
- (LAX1) 'Drink plenty of water' [or words to that effect]; and
- (LAX2) 'Prolonged use may cause serious bowel problems'.

2254	FRAXINUS AMERICANA	A, H	
2255	FRAXINUS CHINENSIS SUBSP. RHYNCHOPHYLLA	A, H	
2256	FRAXINUS EXCELSIOR	A, H	
2257	FRAXINUS ORNUS	A, H	
2258	FRITILLARIA CIRRHOSA	A, H	
2259	FRITILLARIA THUNBERGII	A, H	
2260	FRITILLARIA VERTICILLATA	A, H	
2261	FRUCTOOLIGOSACCHARIDES	A, E	
2262	FRUCTOSE	A, E, H	
2263	FUCUS VESICULOSUS	A, E, H	Iodine is a mandatory

			component of Fucus vesiculosus. Only for external use when the concentration of available iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2264	FULLY HYDROGENATED RAPESEED OIL	E	Fully hydrogenated rapeseed oil must only be used in topical medicines for dermal application. The total concentration of fully hydrogenated rapeseed oil in the medicine must not be more than 5%.
2265	FUMARIA OFFICINALIS	A, E, H	
2266	FUMARIC ACID	E, H	Only for use as an active homoeopathic or excipient ingredient.
2267	FUMITORY HERB DRY	A, H	
2268	FUMITORY HERB POWDER	A, H	
2269	FURAMINTON	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2270	FURFURAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2271	FURFURYL ACETATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2272	FURFURYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2273	FURFURYL MERCAPTAN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2274	FUSEL OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2275	GALBANUM OIL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2276	GALBANUM PHENOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2277	GALBANUM RESIN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2278	GALBANUM RESINOID	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2279	GALEGA OFFICINALIS	А, Н	
2280	GALEOPSIS SEGETUM	A, H	
2281	GALIUM APARINE	A, H	
2282	GALIUM ODORATUM	A, H	When used as an active ingredient coumarin is a mandatory component of Galium odoratum and the concentration of coumarin in

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			the medicine must be no more than 0.001%.
2283	GALIUM PALUSTRE	A, H	
2284	GALIUM VERUM	A, H	
2285	GALL STONE	Н	Only for use as an active homoeopathic ingredient.
2286	GALPHIMIA GLAUCA	A, H	
2287	GAMMA-4-DIMETHYL-3- CYCLOHEXENE-1-PROPANOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2288	GAMMA-BUTYROLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2289	GAMMA-CYCLODEXTRIN	Е	
2290	GAMMA-DECALACTONE	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2291	GAMMA-DODECALACTONE	Е	Permitted for use only in combination with other permitted ingredients as a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2292	GAMMA-HEPTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2293	GAMMA-HEXALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2294	GAMMA-IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2295	GAMMA-LINOLEIC ACID	Е	Only for use in topical medicines for dermal application.
2296	GAMMA-LINOLENIC ACID	Е	
2297	GAMMA-N-METHYL IONONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2298	GAMMA-NONALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2299	GAMMA-OCTALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2300	GAMMA-TERPINENE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2301	GAMMA-TOCOPHEROL	E	
2302	GAMMA-UNDECALACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2303	GAMMA-VALEROLACTONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2304	GANODERMA LUCIDUM	A, E, H	
2305	GARCINIA GUMMI-GUTTA	A, L, II	Only for use in oral medicines. Must be obtained from the rind of the fruit only. Must not contain any directions for use for children or pregnant or lactating women.
2306	GARCINIA QUAESITA	A, H	
2307	GARDEN BEAN	Е	
2308	GARDENIA JASMINOIDES	A, E	
2309	GARDENIA TAHITENSIS FLOWER EXTRACT	Е	Only for use in topical medicines for dermal application and not to be

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

volume 3			
			included in medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.002%
2310	GARLIC BULB DRY	A, E, H	
2311	GARLIC BULB FRESH	A, H	
2312	GARLIC BULB POWDER	A, E, H	
2313	GARLIC CLOVE POWDER	A, H	
2314	GARLIC OIL	A, E, H	
2315	GASTRODIA ELATA	A, H	
2316	GAULTHERIA PROCUMBENS	A, E, H	Methyl salicylate is a mandatory component of Gaultheria procumbens. Not to be included in medicines for use in the eye or on damaged skin. When used internally, the concentration of methyl salicylate in the medicine must not be more than 0.001%. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is other than spray, the medicine requires child resistant packaging. When the concentration of methyl salicylate in a liquid preparation is more than 5% and the dosage form is spray, the medicine does not require child resistant packaging if: - the delivery device is engaged into the container in such a way that prevents it from being readily removed; - direct suction through the delivery device results in delivery of no more than one dosage unit; and - actuation of the spray device

			is ergonomically difficult for young children to accomplish. The following warning statement is required on the medicine label: - (METSAL) 'Contains methyl salicylate' (or words to that effect). When for use in topical medicines for dermal application i) the concentration of methyl salicylate in the medicine must not be more than 25%; ii) the following warning statements are required on the medicine label: - (PREGNT2) 'Do not use if pregnant or likely to become pregnant' (or words to that effect); - (CHILD4) 'Do not use [this product/insert name of product] in children 6 years of age or less'; - (SENS) 'Application to skin may increase sensitivity to sunlight.' (or words to that effect); - (AVOID) 'Avoid prolonged exposure in the sun' (or words to that effect); iii) if the concentration of methyl salicylate in the medicine is greater than 1%, the following warning statement is required on the medicine label: - (IRRIT) 'If irritation develops, discontinue use'.
2317	GELATIN	A, E	Talling in a sure 12
2318	GELIDIUM AMANSII	А, Н	Iodine is a mandatory component of Gelidium amansii. Only for external use when the

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2319	GELLAN GUM	E	
2320	GELSEMIUM DRY	А, Н	The concentration of Gelsemium dry in the medicine must be no more than 1mg/Kg or 1mg/L or 0.0001%.
2321	GELSEMIUM POWDER	A, H	
2322	GELSEMIUM SEMPERVIRENS	A, H	The concentration of equivalent dry Gelsemium sempervirens in the product must be no more than 1mg/Kg or 1mg/L or 0.0001%.
2323	GENET ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2324	GENTIAN DRY	A, H	
2325	GENTIAN POWDER	A, H	
2326	GENTIANA LUTEA	A, E, H	
2327	GENTIANA MACROPHYLLA	A, H	
2328	GENTIANA RHODANTHA	A, H	
2329	GENTIANA SCABRA	A, H	
2330	GENTIANELLA AMARELLA	A, H	
2331	GERANIAL	E	Permitted for use only in combination with other

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2332	GERANIC ACID	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2333	GERANIOL	E	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2334	GERANIUM	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2335	GERANIUM MACULATUM	A, E, H	
2336	GERANIUM OIL	A, E, H	
2337	GERANIUM OIL SAPONIFIED	E	Permitted for use only in combination with other permitted ingredients as a fragrance.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2338	GERANIUM OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2339	GERANIUM ROBERTIANUM	A, E, H	
2340	GERANIUM ROSE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2341	GERANIUM SIBIRICUM	A, E, H	
2342	GERANYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2343	GERANYL ACETONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2344	GERANYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2345	GERANYL CROTONATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2346	GERANYL ETHYL ETHER	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2347	GERANYL FORMATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2348	GERANYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2349	GERANYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2350	GERANYL NITRILE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2351	GERANYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2352	GERANYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2353	GEUM RIVALE	A, H	
2354	GEUM URBANUM	A, H	
2355	GHATTI GUM	A, E, H	
2356	GIGARTINA MAMILLOSA	A, H	Iodine is a mandatory component of Gigartina mamillosa. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2357	GINGER DRY	A, E, H	
2358	GINGER OIL	A, E, H	
2359	GINGER OLEORESIN	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
2360	GINGER POWDER	A, E, H	
2361	GINKGO BILOBA	A, E, H	The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27), as in force or existing from time to time. This condition does not apply to powdered or dried leaf.
2362	GLACIAL ACETIC ACID	E, H	The concentration in the medicine must be no more than 1.5%.
2363	GLECHOMA HEDERACEA	A, H	
2364	GLECHOMA LONGITUBA	A, H	
2365	GLEDITSIA AUSTRALIS	A, H	
2366	GLEDITSIA SINENSIS	A, H	
2367	GLEHNIA LITTORALIS	A, H	
2368	GLORIOSA SUPERBA	A, H	Colchicine is a mandatory component of Gloriosa superba and must be declared in the application. The concentration of colchicine in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
2369	GLUCOMANNAN	Е	Only for use when the dosage form is other than tablet.
2370	GLUCONOLACTONE	E	
2371	GLUCOSAMINE HYDROCHLORIDE	A, E	
2372	GLUCOSAMINE SULFATE	A	
2373	GLUCOSAMINE SULFATE POTASSIUM CHLORIDE	A	Potassium chloride is a mandatory component of glucosamine sulfate potassium chloride. When for oral use, the medicine requires the following warning statement on the medicine label: - (POTAS1) 'If you have kidney disease or are taking heart or blood pressure

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			volume .
			medicines - consult your doctor or pharmacist before use. Keep out of reach of children.'
2374	GLUCOSAMINE SULFATE SODIUM CHLORIDE	A	
2375	GLUCOSE	A, E, H	
2376	GLUCOSE GLUTAMATE	E	Only for use in topical medicines for dermal application.
2377	GLUCOSE MONOHYDRATE	A, E, H	
2378	GLUCOSYLRUTIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
2379	GLUTAMIC ACID	A, E	Only for use in topical medicines for dermal application.
2380	GLUTAMIC ACID HYDROCHLORIDE	A, E, H	
2381	GLUTAMINE	A, E, H	
2382	GLUTARAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2383	GLUTATHIONE	A, E	When used as an active ingredient, glutathione can only be used in medicines with an oral route of administration and must be indicated for use in adults only and not in pregnant or lactating women. The medicine requires the

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			following warning statement on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect) - (ADULT) 'Adults only' (or words to that effect).
2384	GLUTEN-FREE WHEAT STARCH	Е	
2385	GLYCERETH-26	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
2386	GLYCEROL	A, E	When used as an active ingredient, it is only for use in topical medicines for dermal application.
2387	GLYCEROL ESTER OF PARTIALLY HYDROGENATED GUM ROSIN	E	Only for use when the dosage form is 'chewing gum'. Must comply with: a) the Glycerol Ester of Partially Hydrogenated Gum Rosin monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia-National Formulary, as in force or existing from time to time.
2388	GLYCEROL ESTER OF PARTIALLY HYDROGENATED WOOD ROSIN	Е	Glycerol ester of partially hydrogenated wood rosin must only be included in medicines

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			when in combination with other permitted ingredients as a proprietary excipient formulation in medicines with a dermal route of administration for topical application.
2389	GLYCERYL BEHENATE	E	Behenic acid is a mandatory component of glyceryl behenate. When for oral ingestion, the maximum recommended daily dose must not provide more than 383.5 milligrams of behenic acid. In medicines for topical use, the concentration of glyceryl behenate must be no more than 5%.
2390	GLYCERYL CAPRYLATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1%.
2391	GLYCERYL DIISOSTEARATE	Е	For use in topical medicines for dermal application.
2392	GLYCERYL DILAURATE	Е	Only for use in topical medicines for dermal application.
2393	GLYCERYL DIOLEATE	Е	Only for use in topical medicines for dermal application.
2394	GLYCERYL DISTEARATE	E	Only for use in topical medicines for dermal application.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2395	GLYCERYL GLUCOSIDE	Е	Only for use in topical
			medicines for dermal application and not to be included in medicines intended for use in the eye.
			The concentration in the medicine must be no more than 5%.
2396	GLYCERYL ISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5.5%.
2397	GLYCERYL LAURATE	Е	Only for use in topical medicines for dermal application.
2398	GLYCERYL LINOLEATE	Е	Only for use in topical medicines for dermal application.
2399	GLYCERYL LINOLENATE	E	Only for use in topical medicines for dermal application.
2400	GLYCERYL MONO AND DICAPRYLOCAPRATE	E	Only permitted for use in medicines limited to oral routes of administration. The maximum recommended daily dose of the medicine must not provide more than 8 mg of glyceryl mono and dicaprylocaprate.
2401	GLYCERYL MONOOLEATE	Е	
2402	GLYCERYL MONOSTEARATE	Е	
2403	GLYCERYL MYRISTATE	Е	Only for use in topical medicines for dermal application.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2404	GLYCERYL OLEATE CITRATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 4% of the formulation.
2405	GLYCERYL PALMITO- STEARATE	Е	
2406	GLYCERYL POLYACRYLATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 0.15%.
2407	GLYCERYL POLYMETHACRYLATE	Е	Only for use in topical medicines for dermal application.
2408	GLYCERYL RICINOLEATE	Е	Only for use in topical medicines for dermal application.
2409	GLYCERYL ROSINATE	E	Only for use when the dosage form is 'chewing gum'. Must comply with: a) the Glycerol Ester of Gum Rosin monograph in the Food Chemicals Codex published by the United States Pharmacopeial Convention, as in force or existing from time to time; and b) the requirements for residual solvents and catalysts in the British Pharmacopoeia or the United States Pharmacopeia National Formulary, as in force or existing from time to time.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2410	GLYCERYL SORBITAN OLEOSTEARATE	Е	Only for use in topical medicines for dermal application.
2411	GLYCERYL STARCH	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 4%. The residual levels of epichlorohydrin are to be kept below the level of detection.
2412	GLYCERYL STEARATE CITRATE	Е	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 5%.
2413	GLYCERYL TRIACETYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application. The concentration in the medicine must be no more than 6%.
2414	GLYCERYL TRIACETYL RICINOLEATE	Е	Only for use in topical medicines for dermal application.
2415	GLYCERYL TRINITRATE	Н	Only for use as an active homoeopathic ingredient. The total concentration of glyceryl trinitrate in the medicine must not be more than 100 micrograms/kg or 100 micrograms/L or 0.00001%.
2416	GLYCERYL UNDECYLENATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye or on

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			damaged skin. The concentration of glyceryl undecylenate in a medicine must be no more than 3%.
2417	GLYCINE	A, E	
2418	GLYCINE MAX	A, E, H	
2419	GLYCOGEN	Е	Only for use in topical medicines for dermal application.
2420	GLYCOL DISTEARATE	Е	Only for use in topical medicines for dermal application.
2421	GLYCOLIC ACID	E	Only for use in topical medicines for dermal application. Sponsors should consider the impact of excipients on the sensitivity of the skin to sunlight and should ensure the finished product is safe for its intended purpose. When present as an excipient in sunscreens, the concentration in the medicine must be no more than 5%. When used as an excipient ingredient in other medicines the concentration in the medicines the concentration in the medicine must be no more than 20%. If the concentration is more than 5% but no more than 20% the pH of the medicine must be 3.5 or greater.
<u>2422</u> <u>2423</u>	GLYCYRRHIZA GLABRA GLYCYRRHIZA SPECIES	A, E, H E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more than 5%.
2424	GLYCYRRHIZA URALENSIS	A, E, H	
2425	GLYCYRRHIZINIC ACID	Е	
2426	GNAPHALIUM AFFINE	A, H	
2427	GNAPHALIUM POLYCEPHALUM	A, H	
2428	GNAPHALIUM ULIGINOSUM	A, H	
2429	GOAT	Н	Only for use as an active homoeopathic ingredient.
2430	GOAT MILK	Е	
2431	GOLD	E, H	Only for use as an active homoeopathic or excipient ingredient.
2432	GOLD CHLORIDE	Н	Only for use as an active homoeopathic ingredient.
2433	GOLDEN ROD HERB DRY	A, E, H	
2434	GOLDEN SEAL ROOT DRY	A, H	
2435	GOLDEN SEAL ROOT POWDER	A, H	
2436	GOLDEN SYRUP	Е	When the route of administration of the medicine is oral or sublingual, sucrose is a mandatory component of golden syrup.
2437	GOMPHRENA GLOBOSA	A, H	
2438	GOOSEBERRY	E	
2439	GOSSYPIUM HERBACEUM	A, E, H	
2440	GRAPE	Е	
2441	GRAPE SEED OIL	Е	
2442	GRAPE WINE RED	Е	Ethanol is a mandatory component of grape wine red.
2443	GRAPE WINE SHERRY	Е	Ethanol is a mandatory component of grape wine sherry.
2444	GRAPE WINE WHITE	Е	Ethanol is a mandatory component of grape wine

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			white.
2445	GRAPEFRUIT	Е	
2446	GRAPEFRUIT OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2447	GRAPEFRUIT OIL COLDPRESSED	A, E, H	
2448	GRAPEFRUIT OIL CONCENTRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2449	GRAPEFRUIT OIL TERPENELESS	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2450	GRAPEFRUIT OIL TERPENES AND TERPENOIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more 1%.
2451	GRAPHITE	Н	Only for use as an active homoeopathic ingredient.
2452	GRATIOLA LINIFOLIA	A, H	
2453	GREATER NETTLE HERB DRY	A, H	
2454	GREATER NETTLE HERB POWDER	A, H	
2455	GREATER NETTLE ROOT DRY	A, H	
2456	GREATER NETTLE ROOT POWDER	A, H	
2457	GREEN LIPPED MUSSEL	A	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2022; or - released for supply on or after 1 March 2023. (a) The following warning statement is required on the medicine label: - (MOLLUSC) 'Contains mollusc products'.
2458	GREEN LIPPED MUSSEL DRIED	A	The requirement specified in paragraph (a) below applies to a medicine that contains the ingredient that is: - listed in the Register on or after 1 March 2022; or - released for supply on or after 1 March 2023. (a) The following warning statement is required on the medicine label: - (MOLLUSC) 'Contains mollusc products'.
2459	GREEN LIPPED MUSSEL OIL	A	The requirement specified in paragraph (a) below applies to a medicine that contains the

			ingredient that is: - listed in the Register on or after 1 March 2022; or - released for supply on or after 1 March 2023. (a) The following warning statement is required on the medicine label: - (MOLLUSC) 'Contains mollusc' or 'Contains mollusc products'.
2460	GREEN S	Е	Only for use as a colour in topical and oral medicines.
2461	GRIFOLA FRONDOSA	A	When the route of administration is oral or sublingual, the medicine requires the following warning statement on the medicine label: -(WARF) 'Do not take while on warfarin therapy without medical advice.'
2462	GRINDELIA CAMPORUM	A, H	
2463	GRINDELIA ROBUSTA	A, H	
2464	GRISALVA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2465	GROUND IVY HERB DRY	A, H	
2466	GROUND IVY HERB POWDER	A, H	
2467	GUAIAC WOOD OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2468	GUAIACOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in the medicine must be no more than 5%.
2469	GUAIACUM OFFICINALE	A, E, H	
2470	GUAIACUM RESIN	A, E, H	
2471	GUAIACUM SANCTUM	A, H	
2472	GUAIENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2473	GUAIYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2474	GUANINE	E	Only for use as an excipient in topical medicines for dermal application.
2475	GUANOSINE	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no

			more than 0.01% in the medicine.
2476	GUAR GALACTOMANNAN	A	When for oral use: (a) the maximum daily dose must provide no more than 25 g of guar galactomannan; (b) the medicine requires the following dosage instructions: - (FIBRE) 'The dose of fibre should be increased gradually. Fluid intake should be increased with an increasing dose of fibre.' (or words to that effect) (c) when the dosage form is a powder preparation, the medicine requires the following dosage instructions: - (DNTPOW) 'Do not take powder alone. Mix with food or fluid.' (or words to that effect).
2477	GUAR GUM	A, E, H	
2478	GUAR HYDROXYPROPYLTRIMONIUM CHLORIDE	Е	Only for use as an excipient in topical medicines for dermal application.
2479	GUAREA RUSBYI	A, H	
2480	GUAVA	E	
2481	GURJUN BALSAM	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2482	GYMNADENIA NIGRA	A	
2483	GYMNEMA SYLVESTRE	A, H	
2484	GYMNOCLADUS DIOICA	A, H	
			The herbal substance must be

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

	PENTAPHYLLUM		derived from the aerial parts of the vine only (stem, leaves, fruit).
2486	HAHNEMANN'S SOLUBLE MERCURY	Н	Only for use as an active homoeopathic ingredient.
2487	HALIBUT-LIVER OIL	A, E	Colecalciferol and Vitamin A are mandatory components of Halibut-liver oil. When for internal use, the maximum recommended daily dose must be no more than 25 micrograms of Vitamin D. When for use in topical medicines, the concentration of Vitamin A in the medicine must be no more than 1%. When for internal use, the maximum daily dose must be no more than 3000 micrograms of Retinol Equivalents. When preparations for internal use in adults contain more than 33 micrograms of retinol equivalents per dosage unit in divided preparations or per gram of an undivided preparation, the medicine requires the following warning statements on the medicine requires the following warning statements on the medicine label: - (VITA2) 'WARNING: If you are pregnant - or considering becoming pregnant - do not take Vitamin A supplements without consulting your doctor or pharmacist [or words to that effect].' NOTE: Position this warning at the beginning of the directions for use. - (VITA4) 'WARNING - When taken in excess of 3000 micrograms retinol equivalents - Vitamin A can cause birth defects.' NOTE: Position this

			warning at the beginning of the directions for use. - (VITA3) 'The recommended daily amount of Vitamin A from all sources is 700 micrograms retinol equivalents for women and 900 micrograms retinol equivalents for men.'
2488	HAMAMELIS LEAF DRY	A, H	
2489	HAMAMELIS LEAF POWDER	A, H	
2490	HAMAMELIS VIRGINIANA	A, E, H	
2491	HAMAMELIS WATER	A, E, H	
2492	HANDROANTHUS HEPTAPHYLLUS	A, H	
2493	HANDROANTHUS IMPETIGINOSUS	A, E, H	
2494	HARD FAT	Е	
2495	HARD PARAFFIN	Е	
2496	HARICOT BEAN	Е	
2497	HARPAGOPHYTUM PROCUMBENS	A, E, H	
2498	HARUNGANA MADAGASCARIENSIS	A, H	
2499	HAZEL NUT	Е	
2500	HAZEL NUT OIL	E	
2501	HEAVY KAOLIN	E	
2502	HEAVY MAGNESIUM OXIDE	А, Е, Н	Magnesium is a mandatory component of heavy magnesium oxide. When used in a medicine: (a) with an oral route of administration; (b) not indicated for laxative (or related) use; and (c) where the maximum recommended daily dose for: (i) children aged between 1 and 3 years (inclusive) provides 65 mg or more total magnesium from inorganic magnesium salts;

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			(ii) children aged between 4 and 8 years (inclusive) provides 110 mg or more total magnesium from inorganic magnesium salts; or (iii) individuals aged 9 years or older provides 350 mg or more total magnesium from inorganic magnesium salts; the following warning statement is required on the medicine label: - (LAX6) 'Contains magnesium, which may have a laxative effect or cause diarrhoea' (or words to that effect). When the route of administration is oral, the medicine must not be directed for use in infants younger than 12 months of age.
2503	HECTORITE	Е	Only for use in topical medicines for dermal application.
2504	HEDEOMA PULEGIOIDES	A	
2505	HEDERA HELIX	А, Н	Emetine is a mandatory component of Hedera helix. The concentration of emetine in the medicine must be no more than 0.2%.
2506	HEDTA	Е	Only for use as an excipient in topical medicines for dermal application.
2507	HEKLA LAVA	Н	Only for use as an active homoeopathic ingredient.
2508	HELESTRALIS	Е	Permitted for use only in combination with other permitted ingredients as a fragrance.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2509	HELIANTHEMUM NUMMULARIUM	A, H	
2510	HELIANTHUS ANNUUS	A, E, H	
2511	HELIANTHUS TUBEROSUS	A, H	
2512	HELICHRYSUM ANGUSTIFOLIUM	A, E, H	
2513	HELICHRYSUM ARENARIUM	A, H	
2514	HELIOTROPYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2515	HELLEBORUS NIGER	А, Н	The maximum recommended daily dose must be no more than 1mg of the equivalent dry herbal material.
2516	HELLEBORUS VIRIDIS	А, Н	The maximum recommended daily dose must be no more than 1 mg of the equivalent dry herbal material.
2517	HELONIAS RHIZOME DRY	A, H	
2518	HELONIAS RHIZOME POWDER	A, H	
2519	HEMIDESMUS INDICUS	A, E, H	
2520	HEPTANAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more 1%.
2521	HEPTANAL DIMETHYL ACETAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2522	HEPTANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2523	HEPTENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2524	HEPTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2525	HEPTYL BUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			flavour concentration in a medicine must be no more than 5%.
2526	HEPTYL UNDECYLENATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration of the medicine must be no more than 25%.
2527	HERACLEUM HEMSLEYANUM	A, H	
2528	HERNIARIA GLABRA	A, H	
2529	HESPERIDIN	A, E	
2530	HESPEROCYPARIS MACROCARPA	A, H	
2531	HESPEROYUCCA WHIPPLEI	A, H	
2532	HEX-3-ENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2533	HEXAHYDRO-4,7- METHANOINDEN-6-YL PIVALATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2534	HEXAMETHYLINDANOPYRAN	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2535	HEXAN-1-OL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2536	HEXANE	E	The concentration of the medicine must be no more than 0.029%. When used for a route of administration other than topical, the residual solvent limit for Hexane is 2.9 mg per recommended daily dose.
2537	HEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2538	HEXANOIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2539	HEXASODIUM FYTATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration of Hexasodium fytate in the medicine must be no more than 1.0 %.
2540	HEXENAL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2541	HEXYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2542	HEXYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

25.12	HELINI DIVENSI SE	-	Permitted for use only in
2543	HEXYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a
			medicine must be no more 1%.
2544	HEXYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2545	HEXYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2546	HEXYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2547	HEXYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more than 1%.
2548	HEXYL LAURATE	Е	Only for use as an excipient in topical medicines for dermal application.
2549	HEXYL NICOTINATE	Е	
2550	HEXYL PROPIONATE	E	Only for use in medicines in combination with other permitted ingredients as a flavour proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%.
2551	HEXYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2552	HEXYL TIGLATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2553	HEXYLDECANOL	E	Only for use as an excipient in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration of the medicine must be no more than 3%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2554	HEXYLENE GLYCOL	Е	Only for use as an excipient in topical medicines for dermal application.
2555	HEXYLRESORCINOL	A	Permitted for use only in medicated throat lozenges. The medicine of must not contain more than 2.5 mg of hexylresorcinol per lozenge. The maximum recommended daily dose of the medicine must not provide more than 30mg of hexylresorcinol. The medicine label must specify that the medicine is only to be used for 7 days (or less). The following warning statement must be included on the medicine label: - (PREGNT) 'Not recommended for use by pregnant and lactating women' (or words to that effect).
2556	HIBISCUS ESCULENTUS	A, H	
2557	HIBISCUS MUTABILIS	A, H	
2558	HIBISCUS ROSA-SINENSIS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2559	HIBISCUS SABDARIFFA	A, E, H	
2560	HIERACIUM PILOSELLA	A, H	
2561	HIGH AMYLOSE MAIZE STARCH	A, E, H	
2562	HIGH CHROMIUM YEAST	A, E	Chromium is a mandatory component of high chromium yeast. The maximum recommended daily dose must not provide

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2565	HIGH SELENIUM YEAST	A	When for oral or sublingual use, selenium is a mandatory component of high selenium yeast. Oral medicines must contain no more than 150 micrograms of selenium per maximum recommended daily dose. When for oral use, the medicine requires the following warning statement on the medicine label: - (SELE) 'This medicine contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.'
2564	HIGH MOLYBDENUM YEAST	A, E	Molybdenum is a mandatory component of high molybdenum yeast. The maximum daily dose of molybdenum from high molybdenum yeast must be no more than 62.5 micrograms.
2563	HIGH FRUCTOSE MAIZE SYRUP	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
			more than 50 micrograms of chromium from organic chromium sources. High chromium yeast is considered to be an organic form of chromium.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2567	HIPPOPHAE RHAMNOIDES	A, E, H	
2568	HIRSCHFELDIA INCANA	А, Н	Allyl isothiocyanate is a mandatory component of Hirschfeldia incana when the plant part is seed. The concentration of allyl isothiocyanate from all ingredients in the product must be no more than 10 mg/kg or 10 mg/L or 0.001%.
2569	HISTAMINE DIHYDROCHLORIDE	Н	Only for use as an active homoeopathic ingredient.
2570	HISTIDINE	A	
2571	HISTIDINE HYDROCHLORIDE	A, E, H	
2572	HO LEAF OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2573	HO WOOD OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2574	HOLCUS LANATUS	A, H	
2575	HOLY THISTLE HERB DRY	A, H	
2576	HOLY THISTLE HERB POWDER	A, H	

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2578	HOMOSALATE	A, E	For use as an active ingredient only in sunscreens for dermal application. For use as an excipient only in topical medicines for dermal application. Not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 15%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
2579	HONEY	A, E	When the route of administration is oral, the following warning statement is required on the medicine label: - (BABY2) 'Not suitable for infants under the age of twelve months' (or words to that effect).
2580	HONEY BEE	Н	Only for use as an active homoeopathic ingredient.
2581	HONEY EXTRACT	Е	Honey extract must not be included in medicines intended for use in the eye. The concentration of honey extract in the medicine must not be more than 1%.
2582	HONEY POWDER	E	Permitted for use only in combination with other

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2583	HOP STROBILE DRY	A, H	
2584	HOP STROBILE POWDER	A, H	
2585	HOPS OIL	A, E, H	
2586	HORDEUM DISTICHON	A, E, H	Gluten is a mandatory component when the plant part is seed, and must be declared in the application when the route of administration is other than topical and mucosal.
2587	HORDEUM VULGARE	A, E, H	Gluten is a mandatory component when the plant part is seed, and must be declared in the application when the route of administration is other than topical and mucosal.
2588	HOREHOUND EXTRACT	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2589	HORSE RADISH	E, H	Volatile oil components (of Armoracia rusticana) is a mandatory component of Horse radish. The maximum recommended daily dose must be no more than 20 mg of volatile oil components (of Armoracia rusticana).
2590	HOTTONIA PALUSTRIS	A, H	
2591	HOUTTUYNIA CORDATA	A, H	

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2592	HOVENIA DULCIS	A, H	
2593	HUMULUS LUPULUS	A, E, H	
2594	HYALURONIC ACID	Е	Only for use as an excipient in topical medicines for dermal application.
2595	HYDNOCARPUS ANTHELMINTICA	А, Н	When the medicine is for other than topical use and the plant part is seed, the maximum recommended daily dose must be no more than 1mg of the equivalent dry seed.
2596	HYDRANGEA ARBORESCENS	A, H	
2597	HYDRANGEA PANICULATA	A, H	
2598	HYDRASTIS CANADENSIS	A, E, H	
2599	HYDRATED SILICA	Е	Only for use when the route of administration is other than inhalation.
2600	HYDROCHLORIC ACID	Е	The concentration of the medicine must be no more than 0.5%.
2601	HYDROCOTYLE UMBELLATA	A, H	
2602	HYDROGEN CYANIDE	Н	Only for use as an active homoeopathic ingredient.
2603	HYDROGEN PEROXIDE	A, E	When used as the active ingredient, it is only for use in topical medicines for dermal application. The concentration of hydrogen peroxide in the medicine must be no more than 3%. When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			time.
2604	HYDROGENATED BUTYLENE/ETHYLENE/STYREN E COPOLYMER	E	Only for use in topical medicines for dermal application. The combined concentration of hydrogenated butylene/ethylene/stryene copolymer and hydrogenated ethylene/propylene/styrene copolymer in the medicine must be no more than 9%.
2605	HYDROGENATED C6-14 OLEFIN POLYMERS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 7%.
2606	HYDROGENATED CASTOR OIL	Е	
2607	HYDROGENATED COCO- GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
2608	HYDROGENATED COCONUT OIL	Е	
2609	HYDROGENATED COTTONSEED OIL	Е	
2610	HYDROGENATED DIMER DILINOLEYL/DIMETHYLCARBO NATE COPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 4% in the product.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2611	HYDROGENATED ETHYLENE/PROPYLENE/STYRE NE COPOLYMER	Е	The combined concentration of hydrogenated ethylene/propylene/styrene copolymer must be no more than 9%.
2612	HYDROGENATED LANOLIN	E	
2613	HYDROGENATED LECITHIN	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2614	HYDROGENATED PALM GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.6%.
2615	HYDROGENATED PALM GLYCERIDES CITRATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.01%.
2616	HYDROGENATED PALM KERNEL OIL	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
2617	HYDROGENATED PALM OIL	Е	Only for use in topical medicines for dermal

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

74

			application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 2%. Polycyclic aromatic hydrocarbons must be kept below the level of detection.
2618	HYDROGENATED POLYDECENE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye.
2619	HYDROGENATED POLYDEXTROSE	A	Only permitted for use in medicines: (a) limited to oral routes of administration; and (b) when the maximum recommended daily dose does not provide more than 15 g of hydrogenated polydextrose.
2620	HYDROGENATED POLYISOBUTENE	E	Only for use in topical medicines for dermal application.
2621	HYDROGENATED SOYA OIL	E	
2622	HYDROGENATED TALLOW GLYCERIDE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 3%.
2623	HYDROGENATED VEGETABLE OIL	Е	
2624	HYDROLIAC	Е	Permitted for use only in combination with other permitted ingredients as a flavour.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2625	HYDROLYSED ADANSONIA DIGITATA LEAF POLYSACCHARIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.01%
2626	HYDROLYSED ALGIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.02%
2627	HYDROLYSED CEREAL SOLIDS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2628	HYDROLYSED CHICKEN CARTILAGE EXTRACT	A	Only to be used in a medicine where BioCell Technology LLC (Client ID 70666), who applied to have the ingredient included in this Determination, is the sponsor of the medicine or has given written authorisation to the sponsor of a medicine to include the ingredient in the medicine. This paragraph ceases to be a requirement for this ingredient after 25 October 2023.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			The route of administration for medicines that contain hydrolysed chicken cartilage extract must be limited to oral. The maximum recommended daily dose of the medicine must not provide more than 2000 mg hydrolysed chicken cartilage extract. The following warning statements (or words to the same effect) are required on the medicine label: - (ADULT) 'Adults only'.
2629	HYDROLYSED COLLAGEN	A, E	
2630	HYDROLYSED ELASTIN	E	Only for use in topical medicines for dermal application.
2631	HYDROLYSED GELATIN	A, E	
2632	HYDROLYSED GLYCOSAMINOGLYCANS	E	Only for use in topical medicines for dermal application.
2633	HYDROLYSED JOJOBA ESTERS	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2634	HYDROLYSED KERATIN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 5%.
2635	HYDROLYSED MAIZE STARCH	Е	
2636	HYDROLYSED MILK PROTEIN	Е	

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2637	HYDROLYSED RICE	A, E, H	
2638	HYDROLYSED RICE PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.125%.
2639	HYDROLYSED SOY PROTEIN	E	Only for use in topical medicines for dermal application not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 0.5%.
2640	HYDROLYSED VEGETABLE PROTEIN	Е	
2641	HYDROLYSED WHEAT PROTEIN	Е	Gluten is a mandatory component of hydrolysed wheat protein.
2642	HYDROLYSED WHEAT PROTEIN/PVP CROSSPOLYMER	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration in the medicine must be no more than 1.2%.
2643	HYDROLYSED YEAST PROTEIN	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 0.3%.
2644	HYDROQUINONE DIMETHYL	E	Permitted for use only in

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

	ETHER		combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2645	HYDROUS WOOL FAT	A, E	When used as an active ingredient, can only be supplied as an uncompounded medicine substance packed for retail sale, and must comply with an uncompounded substance monograph of the British Pharmacopoeia, as in force or existing from time to time.
2646	HYDROXOCOBALAMIN	A	
2647	HYDROXYACETOPHENONE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1%.
2648	HYDROXYAPATITE	A, E	
2649	HYDROXYCITRATE COMPLEX	A	Hydroxycitrate complex must contain one or more of the three salts (calcium, sodium or potassium hydroxycitrate) of hydroxycitric acid.
2650	HYDROXYCITRIC ACID	A	
2651	HYDROXYCITRONELLAL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			v Orume .
			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2652	HYDROXYCITRONELLAL DIMETHYL ACETAL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2653	HYDROXYCITRONELLAL- METHYLANTHRANILATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2654	HYDROXYCITRONELLOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2655	HYDROXYETHYL CETEARAMIDOPROPYLDIMONI UM CHLORIDE	Е	Only for use in topical medicines for dermal application and not to be included in topical medicines

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			intended for use in the eye. The concentration in the medicine must be no more than 0.1%.
2656	HYDROXYETHYL UREA	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 1%.
2657	HYDROXYLATED LANOLIN	E	
2658	HYDROXYLATED MILK GLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.1%.
2659	HYDROXYLYSINE	A, E	
2660	HYDROXYMETHYLCELLULOSE	Е	
2661	HYDROXYOCTACOSANYL HYDROXYSTEARATE	E	Only for use in topical medicines for dermal application.
2662	HYDROXYPALMITOYL SPHINGANINE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration must be no more than 0.1%.
2663	HYDROXYPROLINE	A , E	
2664	HYDROXYPROPYL DISTARCH PHOSPHATE	E	Only permitted for: - use in topical medicines for dermal application; and - medicines for internal use. When for use in topical medicines for dermal application:

			Volume
			- not to be included medicines intended for use in the eye or damaged skin; and - the concentration of hydroxypropyl distarch phosphate in the medicine must be no more than 4%. When for internal use, the maximum recommended daily dose must not contain more than 240mg of hydroxypropyl distarch phosphate.
2665	HYDROXYPROPYL STARCH	E	
2666	HYDROXYPROPYLBETADEX	E	Only for use in topical medicines for dermal application.
2667	HYDROXYSTEARIC ACID	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 9%.
2668	HYETELLOSE	E	
2669	HYLOCEREUS LEMAIREI	Е	Permitted for use only as a colour for oral and topical use.
2670	HYLOCEREUS UNDATUS	A, H	
2671	HYMETELLOSE	E	
2672	HYOSCYAMUS LEAF DRY	А, Н	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscamus leaf dry. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of hyoscine in the medicine must be no more than than 300

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			micrograms/kg or 300 micrograms/L or 0.00003%.
2673	HYOSCYAMUS LEAF POWDER	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscamus leaf powder. The concentration of alkaloids calculated as hyoscyamine in the medicine must be no more than 300 micrograms/Kg or 300 micrograms/L or 0.00003%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2674	HYOSCYAMUS NIGER	A, H	Alkaloids calculated as hyoscyamine and hyoscine are mandatory components of Hyoscyamus niger. The concentration of hyoscyamine in the medicine must be no more than 3 micrograms/kg or 3 micrograms/L or 0.3%. The concentration of hyoscine in the medicine must be no more than 300 micrograms/kg or 300 micrograms/L or 0.00003%.
2675	HYPERICUM ASCYRON	A, H	
2676	HYPERICUM JAPONICUM	A, H	
2677	HYPERICUM PERFORATUM	A, E, H	When used for oral ingestion, the medicine requires the following warning statement on the medicine label: - (STJOHN) 'St John's Wort affects the way many prescription medicines work - including oral contraceptives. Consult your doctor.'

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			v orunie 3
2678	HYPROLOSE	E	
2679	HYPROMELLOSE	Е	
2680	HYPROMELLOSE PHTHALATE	Е	
2681	HYPTIS SUAVEOLENS	A, H	
2682	HYSSOPUS OFFICINALIS	A , E, H	
2683	IBERIS AMARA	A, H	
2684	ICHTHAMMOL	Н	Only for use as an active homoeopathic ingredient.
2685	ILEX AQUIFOLIUM	A, H	
2686	ILEX CHINENSIS	A, H	
2687	ILEX PARAGUARIENSIS	A, E, H	Caffeine is a mandatory component of Ilex paraguariensis. When the medicine is packaged for supply as a divided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 33%. When for internal use or oral application, the maximum recommended daily dose of the medicine must provide no more than 400 mg of total caffeine. When the medicine is packaged for supply as an undivided preparation and is for internal use or oral application, the medicine must not contain a concentration of total caffeine greater than 1%. When the medicine is for internal use or oral application, a maximum recommended dose of the medicine must not provide more than 100 mg of total caffeine within a 3 hour period. When the maximum recommended dose of the

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

medicine provides greater than
10 mg of total caffeine and the
medicine is for internal use or
oral application, the following
warning statements are
required on the label:
- (ADULT) 'Adults only' (or
words to that effect).
- (CAFF) 'Contains [state
quantity per dosage unit or per
mL or per gram of product]
total caffeine [per dosage unit
or per mL or per gram]. A cup
of instant coffee contains
approximately 80mg of
caffeine.'
- (CAFFPREG) 'Caffeine
intake more than 200 mg per
day is not recommended during
pregnancy or breastfeeding.'
When the maximum
recommended daily dose of the
medicine provides greater than
80 mg of total caffeine and the
medicines is for internal use or
oral application, the following
warning statements are
required on the label:
- (CAFFLMT) 'Limit the use of
caffeine-containing products
(including tea and coffee)
when taking this product.'
- (CAFFCYP) 'Caffeine
interacts with enzyme CYP1A2
in the liver. Consult your
health professional before
taking with other medicines'
(or words to that effect).
*

2688	ILEX ROTUNDA	A, H	
2689	ILEX VERTICILLATA	A, H	
2690	ILLICIUM VERUM	А, Н	When the plant preparation is oil or distillate, and the concentration of Illicium verum oil or distillate in the

			preparation is greater than 50%: (a) the nominal capacity of the container must not be more than 50 millilitres; (b) a restricted flow insert must be fitted on the container; and (c) the following warning statement is required on the label: - (CHILD) 'Keep out of reach of children' (or words to that effect).
2691	IMIDUREA	Е	Only for use in topical medicines for dermal application.
2692	IMMORTELLE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2693	IMMORTELLE OIL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2694	IMPATIENS	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2695	IMPATIENS BALSAMINA	A, H	
2696	IMPATIENS GLANDULIFERA	A, H	
2697	IMPERATA CYLINDRICA	A, E, H	
2698	INDIGO CARMINE	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
2699	INDIGO CARMINE ALUMINIUM LAKE	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration.
2700	INDIGOFERA TINCTORIA	A, H	
2701	INDISAN	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2702	INDOLE	E, H	Only for use as an active homoeopathic or excipient ingredient. The maximum recommended daily dose must contain no more than 75 mg indole.
2703	INDOLENE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2704	INDUSTRIAL METHYLATED SPIRIT	E	
2705	INOSITOL	A, E	
2706	INULA BRITANNICA	A, H	
2707	INULA HELENIUM	A, E, H	

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2708	INULA RACEMOSA	A, H	
2709	INULIN	A, E	
2710	INULIN LAURYL CARBAMATE	E	Only for use in topical medicines for dermal application and not to be included in medicines for use in the eye or on damaged skin. The concentration in the medicine must be no more than 1.2%.
2711	INVERT SUGAR	Е	
2712	INVERT SYRUP	E	When the route of administration is oral or sublingual, glucose is a mandatory component of Invert syrup.
2713	IODINE	Н	Only for use as an active homoeopathic ingredient. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is 2.5% or less. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2714	IODOPROPYNYL BUTYLCARBAMATE	E	For use as an excipient ingredient in topical medicines only. The concentration in aqueous medicines must be no more than 10%.
2715	IONONE	Е	Permitted for use only: (a) in topical medicines for dermal application; and (b) in oral medicines in combination with other permitted ingredients as part of a flavour proprietary excipient

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			formulation. When used in a flavour, the total flavour proprietary excipient formulation in a medicine must be no more than 5%.
2716	IOPAMIDOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2717	IPECACUANHA DRY	А, Н	Emetine is a mandatory component of Ipecacuanha Dry. The concentration of emetine in the medicine must be no more than 0.2%.
2718	IPECACUANHA POWDER	А, Н	Emetine is a mandatory component of Ipecacuanha Powder. The concentration of emetine in the medicine must be no more than 0.2%.
2719	IPECACUANHA PREPARED	А, Н	Emetine is a mandatory component of Ipecacuanha Prepared. The concentration of emetine in the medicine must be no more than 0.2%.
2720	IPECACUANHA ROOT LIQUID EXTRACT	А, Н	Emetine is a mandatory component of Ipecacuanha root liquid extract. The concentration of emetine in the medicine must be no more than 0.2%.
2721	IPOMOEA BATATAS	A, H	

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2722	IPOMOEA JALAPA	A, H	
2723	IRIDOPHYCUS FLACCIDUM	A, H	Iodine is a mandatory component of Iridophycus flaccidum. Only for external use when the concentration of iodine in the medicine (excluding salts derivatives or iodophors) is more than 2.5%. Only for internal use when the medicine contains less than 300 micrograms of iodine per maximum recommended daily dose.
2724	IRIS DOMESTICA	A, H	
2725	IRIS FLORENTINA	A, H	
2726	IRIS GERMANICA	A, H	
2727	IRIS PALLIDA	A, H	
2728	IRIS TENAX	Н	
2729	IRIS VERSICOLOR	A, H	
2730	IRON	A, H	Only for use in oral medicines. When used as an active ingredient, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Volume 3

contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).

2731 IRON (II) BISGLYCINE SULFATE A TRIHYDRATE

Only for use in oral medicines. Iron is a mandatory component of iron (II) bisglycine sulfate trihydrate.

When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.

If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of

elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that

effect).

2732 IRON (II) GLYCINATE Α

Only for use in oral medicines. Iron is a mandatory component of iron (II) glycinate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron.

If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

Α

Volume 3

2733

required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). Only for use in oral medicines. Iron is a mandatory component of iron (III) glycinate. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of

> elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg

IRON (III) GLYCINATE

of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect). Only for use in oral medicines. 2734 IRON AMINO ACID CHELATE A, H When used internally, iron is a mandatory component of iron amino acid chelate. The concentration of iron in iron amino acid chelate must be no more than 25%. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit

and more than 250 mg of

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2735	IRON OXIDE BLACK	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2736	IRON OXIDE RED	Е	Permitted for use only as a colour in medicines limited to topical and oral routes of administration. When used in undivided preparations for internal use

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2737	IRON OXIDE YELLOW	E	Permitted for use only as a colour in medicines limited to topical and oral routes of administration. When used in undivided preparations for internal use and the concentration of iron oxide in the medicine is more than 1%, it is considered part of the total iron content. When used in divided preparations for internal use, the concentration in the medicine must be no more than 10 mg per dosage unit.
2738	IRON PHOSPHATE	A, E, H	When used internally, iron is a mandatory component of iron phosphate and must be declared. When for internal use, the medicine must contain a daily dose of no more than 24 mg of iron. If the divided dosage form contains more than 5 mg of iron per dosage unit (excluding up to 10 mg of iron oxide when used as an excipient), the primary pack must contain no more than 750 mg of iron. In undivided preparations, the primary pack must contain no more than 750 mg of iron (excluding iron oxides when present as an excipient at a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			quantity of no more than 1%). Divided preparations with a dose of more than 5 mg of elemental iron per dosage unit and more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. Undivided preparations containing more than 250 mg of elemental iron in the total contents of the container are required to have a child resistant closure. When for internal use except for iron-containing multivitamin/mineral products indicated for general nutritional support that do not make specific iron-deficiency related claims, the following warning statement is required on the label: - (IRONDEF) 'Not for the treatment of iron deficiency conditions' (or words to that effect).
2739	IRONE	Е	
2740	IRVINGIA GABONENSIS SEED TRIGLYCERIDES	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 0.375%.
2741	ISATIS TINCTORIA	A, H	
2742	ISOAMBRETTOLIDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			volume .
			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2743	ISOAMYL 2-METHYLBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2744	ISOAMYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2745	ISOAMYL ALCOHOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2746	ISOAMYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2747	ISOAMYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2748	ISOAMYL CAPRYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2749	ISOAMYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2750	ISOAMYL CITRONELLYL KETONE	E	Permitted for use only in combination with other permitted ingredients as a fragrance.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2751	ISOAMYL FORMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2752	ISOAMYL HEXANOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2753	ISOAMYL ISOBUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2754	ISOAMYL ISOVALERATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2755	ISOAMYL LAURATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 12%.
2756	ISOAMYL METHOXYCINNAMATE	A	Only for use as an active ingredient in sunscreens for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must not be more than 10%. When used in primary sunscreen products, the following warning statements are required on the label: - (AVOID) 'Avoid prolonged exposure in the sun' (or words to this effect); and - (SUNPRO) 'Wear protective clothing - hats and eyewear when exposed to the sun' (or words to this effect).
2757	ISOAMYL PHENYLACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more 1%.
2758	ISOAMYL PHENYLETHYL ETHER	E	Permitted for use only in combination with other permitted ingredients as part of a fragrance proprietary excipient formulation. The total fragrance proprietary excipient formulation in a medicine must be no more than 1%.
2759	ISOAMYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2760	ISOAMYL SALICYLATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2761	ISOBERGAMIATE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2762	ISOBORNEOL	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2763	ISOBORNYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2764	ISOBORNYL CYCLOHEXANOL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2765	ISOBUTANE	Е	Only for use in topical medicines for dermal application.
2766	ISOBUTYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			fragrance concentration in a medicine must be no more 1%.
2767	ISOBUTYL ALCOHOL	E	The residual solvent limit for Isobutyl alcohol is 50mg per recommended daily dose. The concentration of isobutyl alcohol must be no more than 0.5% of the formulation.
2768	ISOBUTYL BENZOATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
2769	ISOBUTYL BENZYL CARBINOL	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used as a flavour the total flavour concentration in a medicine must be no more than 5%.
2770	ISOBUTYL BUTYRATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2771	ISOBUTYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2772	ISOBUTYL CINNAMATE	E	Permitted for use only in
2112	ISOBOTTE CINIVAINATE	L	combination with other
			permitted ingredients as a flavour.
			If used in a flavour the total
			flavour concentration in a
			medicine must be no more than
			5%.
2773	ISOBUTYL FORMATE	Е	Permitted for use only in
			combination with other
			permitted ingredients as a flavour.
			If used in a flavour the total
			flavour concentration in a
			medicine must be no more than
			5%.
2774	ISOBUTYL	Е	Only for use in topical
	HYDROXYBENZOATE		medicines for dermal
			application.
2775	ISOBUTYL ISOBUTYRATE	Е	Permitted for use only in
			combination with other
			permitted ingredients as a flavour or a fragrance.
			If used in a flavour the total
			flavour concentration in a
			medicine must be no more than 5%.
			If used in a fragrance the total
			fragrance concentration in a
			medicine must be no more 1%.
2776	ISOBUTYL ISOVALERATE	E	Permitted for use only in
			combination with other permitted ingredients as a
			flavour.
			If used in a flavour the total
			flavour concentration in a
			medicine must be no more than 5%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2778	ISOBUTYL PROPIONATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2779	ISOBUTYL QUINOLINE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2780	ISOBUTYL SALICYLATE	Е	Only for use in topical medicines for dermal application.
2781	ISOBUTYLENE/ISOPRENE COPOLYMER	E	Only for oral use when the dosage form is chewing gum. The concentration must be consistent with best practice for the production of gum delivery systems.
2782	ISOBUTYRALDEHYDE	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			flavour concentration in a medicine must be no more than 5%.
2783	ISOBUTYRIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2784	ISOCETYL ALCOHOL	E	Only for use in topical medicines for dermal application.
2785	ISOCETYL LINOLEOYL STEARATE	E	Only for use in topical medicines for dermal application.
2786	ISOCETYL STEARATE	Е	Only for use in topical medicines for dermal application.
2787	ISOCETYL STEAROYL STEARATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 10%.
2788	ISOCYCLOCITRAL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2789	ISODECYL ISONONANOATE	Е	Only for use in topical medicines for dermal application.
2790	ISODECYL NEOPENTANOATE	Е	Only for use in topical medicines for dermal application.
2791	ISODECYL OLEATE	Е	Only for use in topical medicines for dermal application.
2792	ISODECYL SALICYLATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 2%.
2793	ISODODECANE	Е	Only for use in topical medicines for dermal application.
2794	ISOEICOSANE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 2%.
2795	ISOEUGENOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%. When the medicine is for dermal use, the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			concentration of isoeugenol in the medicine must not be more than 0.02%.
2796	ISOEUGENYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2797	ISOEUGENYL BENZYL ETHER	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2798	ISOHEXADECANE	Е	Only for use in topical medicines for dermal application.
2799	ISOJASMONE	E	Permitted for use only in combination with other permitted ingredients as a flavour proprietary excipient formulation or fragrance proprietary excipient formulation. The total flavour proprietary excipient formulation in a medicine must not be more than 5%. The total fragrance proprietary excipient formulation in a medicine must not be more 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2800	ISOLEUCINE	A, E	
2801	ISOMALT	Е	
2802	ISOMENTHONE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2803	ISOMETHYLIONONE	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2804	ISONONYL ACETATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used as in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2805	ISONONYL ISONONANOATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye or on damaged skin. The concentration must be no more than 15%.
2806	ISOPENTANE	E	For dental use only. The concentration must be no more than 2%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2807	ISOPENTANOIC ACID	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2808	ISOPHORONE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. The total concentration of isophorone in the medicine must not be more than 10 mg/kg or 10 mg/L or 0.001%.
2809	ISOPHYTOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2810	ISOPROPYL 2- METHYLBUTYRATE	Е	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			fragrance concentration in a medicine must be no more 1%.
2811	ISOPROPYL 4- HYDROXYBENZOATE	E	Only for use in topical medicines for dermal application.
2812	ISOPROPYL ACETATE	E	Only for use in topical medicines for dermal application.
2813	ISOPROPYL ALCOHOL	Е	
2814	ISOPROPYL CAPROATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2815	ISOPROPYL CINNAMATE	E	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2816	ISOPROPYL ISOSTEARATE	Е	Only for use in topical medicines for dermal application.
2817	ISOPROPYL LANOLATE	Е	Only for use in topical medicines for dermal application.
2818	ISOPROPYL LAUROYL SARCOSINATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 5.6%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2819	ISOPROPYL MYRISTATE	E	
2820	ISOPROPYL PALMITATE	Е	Only for use in topical medicines for dermal application.
2821	ISOPROPYL PPG-2 ISODECETH-7 CARBOXYLATE	E	Only for use in topical medicines for dermal application and not to be included in topical medicines intended for use in the eye. The concentration must be no more than 10%.
2822	ISOPROPYL STEARATE	E	Only for use in topical medicines for dermal application.
2823	ISOPROPYL TITANIUM TRIISOSTEARATE	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 0.2%.
2824	ISOPROPYL-3-METHYL- BUTANE THIOATE	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2825	ISOPULEGOL	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more 1%.
2826	ISORALDEINE 70	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2827	ISOSTEARIC ACID	Е	Only for use in topical medicines for dermal application.
2828	ISOSTEAROYL HYDROLYSED COLLAGEN	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 0.3%.
2829	ISOSTEARYL ALCOHOL	E	Only for use in topical medicines for dermal application.
2830	ISOSTEARYL NEOPENTANOATE	Е	Only for use in topical medicines for dermal application.
2831	ISOSTEARYL PALMITATE	Е	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration must be no more than 2%.
2832	ISOTRIDECYL ALCOHOL	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			medicine must be no more than 1%.
2833	ISOVALERALDEHYDE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2834	ISOVALERIC ACID	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2835	ISPAGHULA HUSK DRY	A, H	When a dose for children is stated, the following warning statement is required on the label: - (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).
2836	ISPAGHULA HUSK POWDER	A, H	When a dose for children is stated, the following warning statement is required on the label: - (PSYLL1) 'Should only be used for children on medical advice' (or words to that effect).

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2837	IVA AXILLARIS	A, H	
2838	JAMAICA DOGWOOD BARK DRY	A, H	
2839	JAMAICA DOGWOOD BARK POWDER	A, H	
2840	JASMINE ABSOLUTE	E	Permitted for use only in combination with other permitted ingredients as a flavour or a fragrance. If used in a flavour the total flavour concentration in a medicine must be no more than 5%. If used in a fragrance the total fragrance concentration in a medicine must be no more 1%.
2841	JASMINE LACTONE	Е	Only for use in topical medicines for dermal application.
2842	JASMINE OIL	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2843	JASMINUM GRANDIFLORUM	Е	Permitted for use only in combination with other permitted ingredients as a flavour. If used in a flavour the total flavour concentration in a medicine must be no more than 5%.
2844	JASMINUM OFFICINALE	A, E, H	
2845	JASSOLIA	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

			fragrance concentration in a medicine must be no more than 1%.
2846	JATEORHIZA PALMATA	A, H	
2847	JATROPHA CURCAS	Н	Only for use as an active homoeopathic ingredient
2848	JERUSALEM ARTICHOKE	E	
2849	JOJOBA ESTERS	E	Only for use in topical medicines for dermal application and not to be included in medicines intended for use in the eye. The concentration in the medicine must be no more than 25%.
2850	JUGLANS CINEREA	A, E, H	
2851	JUGLANS NIGRA	A, E, H	
2852	JUGLANS REGIA	A, H	
2853	JUNCUS EFFUSUS	A, H	
2854	JUNIPER BERRY OIL	A, E, H	
2855	JUNIPER BERRY OIL TERPENELESS	E	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.
2856	JUNIPERUS CALIFORNICA	A, H	
2857	JUNIPERUS COMMUNIS	A, E, H	
2858	JUNIPERUS DEPPEANA	Е	Permitted for use only in combination with other permitted ingredients as a fragrance. If used in a fragrance the total fragrance concentration in a medicine must be no more than 1%.

Schedule 1 Specified permissible ingredients and requirements applying to these ingredients when contained in a medicine

2859	JUNIPERUS OXYCEDRUS	А, Н	
2860	JUNIPERUS VIRGINIANA	A, E, H	
2861	JUSTICIA ADHATODA	А, Н	